Literature DB >> 18370459

[Not Available].

M Tomlin1, A Basarab, D Warnock.   

Abstract

Year:  1997        PMID： 18370459     DOI： 10.2165/00044011-199713020-00008

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  7 in total

1.  Elimination of liposomal amphotericin by hemodiafiltration.

Authors:  M Tomlin; G S Priestley
Journal:  Intensive Care Med       Date:  1995-08       Impact factor: 17.440

2.  Liposomal amphotericin B and continuous venous-venous haemofiltration.

Authors:  H Humphreys; D A Oliver; R Winter; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1994-05       Impact factor: 5.790

3.  In-vitro resistance to imidazole antifungals in Candida albicans.

Authors:  E M Johnson; M D Richardson; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1984-06       Impact factor: 5.790

Review 4.  Clinical use of liposomal and lipid-complexed amphotericin B.

Authors:  S de Marie; R Janknegt; I A Bakker-Woudenberg
Journal:  J Antimicrob Chemother       Date:  1994-05       Impact factor: 5.790

5.  Management of deep Candida infection in surgical and intensive care unit patients. British Society for Antimicrobial Chemotherapy Working Party.

Authors: 
Journal:  Intensive Care Med       Date:  1994-08       Impact factor: 17.440

Review 6.  Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.

Authors:  R Janknegt; S de Marie; I A Bakker-Woudenberg; D J Crommelin
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

7.  Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard.

Authors:  G G Granich; G S Kobayashi; D J Krogstad
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.